Sign in
4/A

Changes in Ownership

NEKTAR THERAPEUTICS Filed Acc 0001209191-16-091744

Options or other derivatives

  • SVP & Chief Scientific Officer acquired 19,250 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Doberstein Stephen K · SVP & Chief Scientific Officer

Table II: Derivative

2 lines
Date Transaction Shares Exercise Expires Underlying Owned after D/I
2015-12-15 Grant or award : show line 1 in the form Restricted Stock Unit +10,500 2023-12-14 10,500 10,500 D
2015-12-15 Grant or award : show line 2 in the form Stock Option +8,750 $15.55 2023-12-14 8,750 8,750 D
Loading xslF345X03/doc4a.xml…